MEDI
NEO
saleprice
KONEF
OTC

Better healthcare for a better future

Wellbeing Digital Sciences is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, such as psychedelic medicine and digital therapeutics supported by clinical research.

We're building a healthcare platform.

Our mission is backed by a network of North American clinical infrastructure that is primarily focused on the development and implementation of innovative clinical solutions, such as psychedelic medicine and digital therapeutics supported by clinical research.

Put simply, we exist to make breakthrough treatments more accessible and to offer patients transformational experiences.

Key Acquisitions

Strategic Partnerships

Our World Class Contract Research Division

As a full-service premium contract research organization, KGK Science is one of the most reliable resources for brands looking for an experienced, trustworthy team of scientific researchers, consultants, and regulatory specialists to develop customized claim substantiation and path-to-market strategies.

Leading Clinical Research Since 1997

350+

Clinical Trials

The team at KGK Science puts their expertise to work for you, providing a professionally managed project from end-to-end that meets the highest quality standards.

150+

Publications

Articles for medical and scientific journals tailored to your specifications and written by medical professionals. Articles may be commissioned for original research and/or literature reviews.

25,000+

Participant Database

KGK’s specialized marketing and recruitment team develops customized strategies to connect the right population to meet the needs of your study.

10M+

Data Points

Rigorous statistical analysis performed transparently to ICH standards for both initial data analysis and previously analyzed data.

NEWS Releases

Latest News & Updates from Wellbeing Digital Sciences

Load More

Get informed

Ketamine Therapies in the News & Media

Video

Interview: Najla Guthrie: CEO: Wellbeing Digital Sciences

Highly Capitalized

Article

RESEARCH Pioneering trial to investigate Psilocybin for Fragile X Syndrome

Psychedelic Health

Article

3 Psychedelic Companies and Their Strategies for Success

Green Market Report

Article

10 Psychedelics CEOs To Pay Attention To In 2022

Benzinga

Video

Wellbeing Digital Sciences subsidiary KGK Sciences lands another key Phase 2 clinical trial

Proactive Investors

Article

Wonderland 2022 Takeaways: What’s After Approvals?

Investing News

Video

Why Do We Need a Women In Psychedelics Network?: Mindshifting Moments #11

Psychedelic Invest

Article

3 Psychedelic Companies and Their Strategies for Success

Green Market Report

Article

The Marriage of Herbal Nutraceuticals and Psychedelics

Green Market Report

Article

15 Global Psychedelics Executives To Keep An Eye On In 2022

Benzinga

Video

Wellbeing Digital Science welcomes Najla Guthrie as the company’s new CEO

Proactive Investors

Video

Could a drug prevent depression and PTSD?

TED

Video

The Experimental Ketamine Cure for Depression

VICE

Video

Techies Are Using Ketamine to Fight Their Depression

WIRED

Video

Here's How Ketamine Actually Works as a Treatment

MedCircle

Audio

Depression Treatments Inspired By Club Drug Move Ahead In Tests

NPR

Audio

Ketamine Relieves Depression By Restoring Brain Connections

NPR

If you're interested in being a financial partner, clinic partner, or community advocate, we'd love to talk.

Awesome, you subscribed!
Error! Please try again.
Wellbeing Digital Sciences logo